Vivos 2025 Q3 Earnings Net Loss Widens 106.4% Despite 75.7% Revenue Surge

Vivos Therapeutics (VVOS) exceeded revenue expectations in Q3 2025 with a 75.7% year-over-year increase to $6.78 million, driven by its strategic pivot to medical partnerships and acquisitions. However, the company reported a widened net loss of $5.4 million (-$0.49/share), reflecting ongoing operational challenges. CEO R. Huntsman emphasized the quarter as a “watershed” for the business, signaling optimism about future growth despite current financial pressures.

Revenue

Vivos’ total revenue surged to $6.78 million in Q3 2025, up from $3.86 million in the prior-year period, fueled by its acquisition of Sleep Center of Nevada and expansion of Sleep and Airway Medicine Centers (SAMC). Product revenue contributed $2.19 million, while service revenue reached $4.59 million, led by sleep testing services at $2.56 million. Appliance sales added $1.41 million, and treatment centers generated $1.32 million. Guides and VIP services contributed $790,000 and $82,000 respectively, underscoring a diversified revenue stream. The strategic shift to direct medical affiliations has clearly amplified top-line growth.

Earnings/Net Income

The company’s losses deepened to $0.49 per share in Q3 2025 from $0.40 per share in Q3 2024, with net loss expanding to $5.40 million (a 106.4% increase) compared to $2.62 million the prior year. This reflects the costs of scaling operations, credentialing delays, and upfront acquisition expenses. The EPS decline indicates worsening financial performance amid aggressive expansion.

Post-Earnings Price Action Review

The stock price of Vivos fell 2.07% on the day of the earnings report, 6.35% over the following week, and 17.19% month-to-date as of Nov 19, 2025. Despite this, historical data shows that buying shares on the day of revenue announcements and holding for 30 days has yielded a 17.5% cumulative return over three years, albeit with a 11.9% maximum drawdown. This suggests a potentially robust short-term strategy for capturing earnings-driven volatility.

CEO Commentary

CEO R. Huntsman described Q3 2025 as a “watershed quarter and inflection point,” crediting the acquisition of Sleep Center of Nevada and the establishment of SAMC for driving revenue growth. He highlighted the strategic pivot to direct medical affiliations as a “validation of our core thesis,” noting that patients increasingly choose Vivos over CPAP for sleep apnea treatment. Challenges include scaling operations and credentialing delays, but Huntsman remains optimistic about achieving cash flow breakeven in 2026.

Guidance

Management anticipates a 3–6 month ramp period for new providers to reach full revenue potential, with SAMC operations targeting 50–60% contribution margins. While no specific revenue targets were provided, the CEO expects “dramatic” growth as credentialed providers expand and partnerships with cardiology and specialty clinics deepen.

Additional News

1. Acquisition Expansion: Vivos acquired Sleep Center of Nevada (SCN) in June 2025, integrating it into its SAMC model to boost diagnostic and treatment services. This acquisition directly fueled a 78% sequential revenue increase in Q3.

2. Strategic Partnerships: The company announced a management agreement with MISleep Solutions LLC in Michigan, marking its first expansion beyond Las Vegas. This joint venture will offer Vivos’ full suite of OSA treatments, with Vivos holding a supermajority equity stake.

3. Operational Scaling: CEO Huntsman emphasized the need to rapidly add facilities, staff, and providers at SCN to meet surging patient demand, with appointments booked through late February 2026.

Article Polishing

• Enhanced transitions between sections for smoother readability.

• Corrected punctuation and spacing inconsistencies.

• Replaced repetitive phrasing in revenue segments.

• Ensured numerical accuracy and formal tone throughout.

• Embedded placeholders per specified rules.